How is Cooper Companies’ Stock Performance Compared to Other Medical Instruments & Supplies Stocks?
/Cooper%20Companies%2C%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
San Ramon, California-based The Cooper Companies, Inc. (COO) is a global medical device company that develops, manufactures, and markets contact lenses. With a market cap of around $14 billion, the company operates in two segments, CooperVision and CooperSurgical.
Companies worth $10 billion or more are generally described as “large-cap” stocks, and Cooper Companies fits this criterion perfectly. The company specializes in contact lenses and eye care products, and also offers a wide range of medical devices and fertility solutions for women’s health. It focuses on innovation, patient outcomes, and global expansion to drive long-term growth across healthcare markets.
Shares of Cooper Companies have declined 37.9% from its 52-week high of $112.38. COO stock has dropped 12.8% over the past three months, a steeper decline than the First Trust Indxx Global Medical Devices ETF’s (MDEV) 2.3% decrease.
Longer term, shares of COO have plunged 24.1% on a YTD basis, notably underperforming MDEV’s nearly 2.7% downtick over the same time frame. Moreover, Cooper’s stock has fallen 23.8% over the past 52 weeks, compared to MDEV’s marginal dip.
Despite some fluctuations, the stock has been trading below its 50-day moving average since late October last year and its 200-day moving average since early December last year.
Despite posting strong Q2 2025 results on May 29, shares of COO tumbled 14.6% the next day. Quarterly revenue rose 6.3% year-over-year to $1 billion, exceeding Street expectations, while adjusted EPS increased 19.6% year-over-year to $0.96, also beating estimates. However, the stock declined as the company lowered its full-year organic growth outlook to 5% to 6%, down from the previous forecast of 6% to 8%, which dampened investor sentiment.
Compared to its rival, Align Technology, Inc. (ALGN) has slightly underperformed the COO stock over the past 52 weeks, decreasing 25.7%. However, shares of ALGN have declined 13.7% YTD, a less pronounced dip compared to COO stock.
Although COO has underperformed, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “Moderate Buy” from the 16 analysts covering the stock. As of writing, the stock is trading below the mean price target of $94.87.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.